Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers

PURPOSE: Midostaurin (PKC412), a multitargeted tyrosine kinase inhibitor that targets FMS-related tyrosine kinase 3 and KIT, is in clinical trials for the treatment for acute myeloid leukemia and advanced systemic mastocytosis. In vitro studies showed that midostaurin is predominantly metabolized by...

Descripción completa

Detalles Bibliográficos
Autores principales: Dutreix, Catherine, Munarini, Florence, Lorenzo, Sebastien, Roesel, Johannes, Wang, Yanfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834177/
https://www.ncbi.nlm.nih.gov/pubmed/24085261
http://dx.doi.org/10.1007/s00280-013-2287-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834177/
https://www.ncbi.nlm.nih.gov/pubmed/24085261
http://dx.doi.org/10.1007/s00280-013-2287-6

Ejemplares similares